Duration of Seropositivity Following Yellow Fever Vaccination in U.S. Military Service Members

Overview

Journal Vaccine

Specialty Allergy & Immunology

Date 2020 Nov 26

PMID 33239225

Authors

Nicole P Lindsey

Lori Perry

Marc Fischer

Tabitha Woolpert

Brad J Biggerstaff

Gary Brice

Kelly Fitzpatrick

Olga I Kosoy

Janeen J Laven

Christopher A Myers

Ewell M Hollis

J Erin Staples

Affiliations

Soon will be listed here.

Abstract

Background: The United States military regularly deploys thousands of service members throughout areas of South America and Africa that are endemic for yellow fever (YF) virus. To determine if booster doses might be needed for service members who are repetitively or continually deployed to YF endemic areas, we evaluated seropositivity among US military personnel receiving a single dose of YF vaccine based on time post-vaccination.

Methods: Serum antibodies were measured using a plaque reduction neutralization test with 50% cutoff in 682 military personnel at 5-39 years post-vaccination. We determined noninferiority of immune response by comparing the proportion seropositive among those vaccinated 10-14 years previously with those vaccinated 5-9 years previously. Noninferiority was supported if the lower-bound of the 2-tailed 95% CI for p - p was ≥-0.10. Additionally, the geometric mean antibody titer (GMT) at various timepoints following vaccination were compared to the GMT at 5-9 years.

Results: The proportion of military service members with detectable neutralizing antibodies 10-14 years after a single dose of YF vaccine (95.8%, 95% CI 91.2-98.1%) was non-inferior to the proportion 5-9 years after vaccination (97.8%, 95% CI 93.7-99.3%). Additionally, GMT among vaccine recipients at 10-14 years post vaccination (99, 95% CI 82-121) was non-inferior to GMT in YF vaccine recipients at 5-9 years post vaccination (115, 95% CI 96-139). The proportion of vaccinees with neutralizing antibodies remained high, and non-inferior, among those vaccinated 15-19 years prior (98.5%, 95%CI 95.5-99.7%). Although the proportion seropositive decreased among vaccinees ≥ 20 years post vaccination, >90% remained seropositive.

Conclusions: Neutralizing antibodies were present in > 95% of vaccine recipients for at least 19 years after vaccination, suggesting that booster doses every 10 years are not essential for most U.S. military personnel.

References

Niedrig M, Lademann M, Emmerich P, Lafrenz M . Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays: neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA. Trop Med Int Health. 2000; 4(12):867-71. DOI: 10.1046/j.1365-3156.1999.00496.x. View

Staples J, Gershman M, Fischer M . Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010; 59(RR-7):1-27. View

P Monath T, Nichols R, Archambault W, Moore L, Marchesani R, Tian J . Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial. Am J Trop Med Hyg. 2002; 66(5):533-41. DOI: 10.4269/ajtmh.2002.66.533. View

Campi-Azevedo A, Peruhype-Magalhaes V, Coelho-Dos-Reis J, Antonelli L, Costa-Pereira C, Speziali E . 17DD Yellow Fever Revaccination and Heightened Long-Term Immunity in Populations of Disease-Endemic Areas, Brazil. Emerg Infect Dis. 2019; 25(8):1511-1521. PMC: 6649311. DOI: 10.3201/eid2508.181432. View

Staples J, Bocchini Jr J, Rubin L, Fischer M . Yellow Fever Vaccine Booster Doses: Recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep. 2015; 64(23):647-50. PMC: 4584737. View

Idoko O, Mohammed N, Ansah P, Hodgson A, Tapia M, Sow S . Antibody responses to yellow fever vaccine in 9 to 11-month-old Malian and Ghanaian children. Expert Rev Vaccines. 2019; 18(8):867-875. DOI: 10.1080/14760584.2019.1640118. View

Reinhardt B, Jaspert R, Niedrig M, Kostner C, Lage-Stehr J . Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J Med Virol. 1998; 56(2):159-67. DOI: 10.1002/(sici)1096-9071(199810)56:2<159::aid-jmv10>3.0.co;2-b. View

Casey R, Harris J, Ahuka-Mundeke S, Dixon M, Kizito G, Nsele P . Immunogenicity of Fractional-Dose Vaccine during a Yellow Fever Outbreak - Final Report. N Engl J Med. 2018; 381(5):444-454. PMC: 7064153. DOI: 10.1056/NEJMoa1710430. View

Monath T . Neutralizing antibody responses in the major immunoglobulin classes to yellow fever 17D vaccination of humans. Am J Epidemiol. 1971; 93(2):122-9. DOI: 10.1093/oxfordjournals.aje.a121232. View

10.

Kareko B, Booty B, Nix C, Lyski Z, Slifka M, Amanna I . Persistence of Neutralizing Antibody Responses Among Yellow Fever Virus 17D Vaccinees Living in a Nonendemic Setting. J Infect Dis. 2019; 221(12):2018-2025. PMC: 7289542. DOI: 10.1093/infdis/jiz374. View

11.

Mauri L, DAgostino Sr R . Challenges in the Design and Interpretation of Noninferiority Trials. N Engl J Med. 2017; 377(14):1357-1367. DOI: 10.1056/NEJMra1510063. View

12.

de Melo A, da Silva M, Magalhaes M, Gil L, Freese de Carvalho E, Braga-Neto U . Description of a prospective 17DD yellow fever vaccine cohort in Recife, Brazil. Am J Trop Med Hyg. 2011; 85(4):739-47. PMC: 3183786. DOI: 10.4269/ajtmh.2011.10-0496. View

13.

Chowdhury P, Meier C, Laraway H, Tang Y, Hodgson A, Sow S . Immunogenicity of Yellow Fever Vaccine Coadministered With MenAfriVac in Healthy Infants in Ghana and Mali. Clin Infect Dis. 2015; 61 Suppl 5:S586-93. PMC: 4639505. DOI: 10.1093/cid/civ603. View

14.

Goldani L . Yellow fever outbreak in Brazil, 2017. Braz J Infect Dis. 2017; 21(2):123-124. PMC: 9427601. DOI: 10.1016/j.bjid.2017.02.004. View

15.

P Monath T, McCarthy K, Bedford P, Johnson C, Nichols R, Yoksan S . Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. Vaccine. 2002; 20(7-8):1004-18. DOI: 10.1016/s0264-410x(01)00457-1. View

16.

Lindsey N, Horiuchi K, Fulton C, Panella A, Kosoy O, Velez J . Persistence of yellow fever virus-specific neutralizing antibodies after vaccination among US travellers. J Travel Med. 2018; 25(1). PMC: 7135922. DOI: 10.1093/jtm/tay108. View

17.

Roukens A, van Halem K, de Visser A, Visser L . Long-Term Protection After Fractional-Dose Yellow Fever Vaccination: Follow-up Study of a Randomized, Controlled, Noninferiority Trial. Ann Intern Med. 2018; 169(11):761-765. DOI: 10.7326/M18-1529. View

18.

Courtois G . [Duration of immunity after yellow fever vaccination]. Ann Soc Belg Med Trop (1920). 1954; 34(1):9-12. View

19.

Gibney K, Edupuganti S, Panella A, Kosoy O, Delorey M, Lanciotti R . Detection of anti-yellow fever virus immunoglobulin m antibodies at 3-4 years following yellow fever vaccination. Am J Trop Med Hyg. 2012; 87(6):1112-5. PMC: 3516084. DOI: 10.4269/ajtmh.2012.12-0182. View

20.

Groot H, RIBERIRO R . Neutralizing and haemagglutination-inhibiting antibodies to yellow fever 17 years after vaccination with 17D vaccine. Bull World Health Organ. 1962; 27:699-707. PMC: 2555840. View